CARsgen Therapeutics Holdings Ltd., a company specializing in innovative CAR T-cell therapies, has announced significant regulatory advancements for its product satricabtagene autoleucel, known as "satri-cel." The Center for Drug Evaluation $(CDE)$ of China's National Medical Products Administration (NMPA) has granted satri-cel Breakthrough Therapy Designation and Priority Review for treating Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two previous lines of therapy. CARsgen is set to submit a New Drug Application (NDA) to the NMPA this month, with anticipation of approval as the first commercially available CAR-T product for solid tumors globally. This development marks a major milestone in the field, offering new hope for patients with limited treatment options.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。